Method of treatment of vascular complications
OwnerMartin Kean Chong Ng, Louise Lorraine Dunn +1inventors
InventorsMartin Kean Chong Ng, Louise Lorraine Dunn, Andrew Buckle
Life of this patent
Estimating the term…
Loading patent…
OwnerMartin Kean Chong Ng, Louise Lorraine Dunn +1inventors
InventorsMartin Kean Chong Ng, Louise Lorraine Dunn, Andrew Buckle
Estimating the term…
The present invention provides methods for the prevention or treatment of one or more vascular complication(s) in a subject at risk of developing diabetes mellitus, impaired glucose tolerance and/or hyperglycemia or a subject suffering from diabetes mellitus, impaired glucose tolerance and/or hyperglycemia, wherein an amount of a composition effective to inhibit, repress, delay or otherwise reduce expression and/or activity and/or level of TXNIP and/or an amount of a composition effective to induce, enhance or otherwise increase expression and/or activity and/or level of TRX is/are administered to a subject in need thereof. The present invention also provides methods for identifying and isolating modulators of TXNIP expression and/or activity and/or level and/or TRX expression and/or activity and/or level for use in such therapeutic and prophylactic methods.
A method of prevention or treatment of one or more vascular complication(s) in a subject at risk of developing diabetes and/or impaired glucose tolerance and/or hyperglycemia or suffering from diabetes and/or impaired glucose tolerance and/or hyperglycemia, said method comprising administering to the subject an amount of a composition effective to inhibit, repress, delay or otherwise reduce expression and/or activity and/or level of a thioredoxin-interacting protein (TXNIP) thereby preventing or alleviating one or more vascular complication(s) in the subject.
12-18. (canceled)
A method of prevention or treatment of one or more vascular complication(s) in a subject at risk of developing diabetes and/or impaired glucose tolerance and/or hyperglycemia or suffering from diabetes and/or impaired glucose tolerance and/or hyperglycemia, said method comprising administering to the subject an amount of a composition effective to induce, enhance or otherwise increase expression and/or activity and/or level of a thioredoxin (TRX) thereby preventing or alleviating one or more vascular complication(s) in the subject.
20-38. (canceled)
(canceled)
(canceled)
A method of vascular repair in a subject comprising administering to the subject an amount of a composition effective to inhibit, repress, delay or otherwise reduce expression and/or activity and/or level of TXNIP thereby enhancing the ability of a cell to develop or proliferate into a functional endothelial cell (EC) or contribute to the formation of functional endothelium or blood vessels or otherwise promote vascular repair or enhance vascular repair.
46-70. (canceled)
A method of vascular repair in a subject comprising administering to the subject an amount of a composition effective to induce, enhance or otherwise increase expression and/or activity and/or level of TRX thereby enhancing the ability of a cell to develop or proliferate into a functional endothelial cell (EC) or contribute to the formation of functional endothelium or blood vessels or otherwise promote vascular repair or enhance vascular repair.
72-98. (canceled)
A method of promoting vascular repair in a subject comprising:
100-131. (canceled)
133-134. (canceled)
136-137. (canceled)
139-140. (canceled)
142-143. (canceled)
A method for identifying a compound or other composition of matter for the treatment or prophylaxis of one or more vascular complications in subjects with diabetes and/or impaired glucose tolerance and/or hyperglycemia and/or for promoting vascular repair and/or for enhancing vascular repair, said method comprising:
145-149. (canceled)
A method for identifying a compound or other composition of matter for the treatment or prophylaxis of one or more vascular complications in subjects with diabetes and/or impaired glucose tolerance and/or hyperglycemia and/or for promoting vascular repair or enhancing vascular repair, said method comprising:
151-154. (canceled)
A method for isolating a compound or other composition of matter for the treatment or prophylaxis of one or more vascular complications in subjects with diabetes and/or impaired glucose tolerance and/or hyperglycemia and/or for promoting vascular repair or enhancing vascular repair, said method comprising:
A method for isolating a compound or other composition of matter for the treatment or prophylaxis of one or more vascular complications in subjects with diabetes and/or impaired glucose tolerance and/or hyperglycemia and/or for promoting vascular repair or enhancing vascular repair, said method comprising:
(canceled)
A method for identifying or isolating a compound or other composition of matter for the treatment or prophylaxis of one or more vascular complications in subjects with diabetes and/or impaired glucose tolerance and/or hyperglycemia and/or for promoting vascular repair and/or for enhancing vascular repair, said method comprising:
159-162. (canceled)
An antagonist or inverse agonist of TXNIP activity or expression for alleviating one or more vascular complications of diabetes and/or impaired glucose tolerance and/or hyperglycemia in a subject in need thereof.
An antagonist or inverse agonist of TXNIP activity or expression for promoting vascular repair in a subject in need thereof.
An antagonist or inverse agonist of TXNIP activity or expression for treatment of a vascular complication of diabetes or other condition associated with impaired glucose tolerance and/or hyperglycemia.
An antagonist or inverse agonist of TXNIP activity or expression for treatment of a vascular disease associated with diabetes or other condition associated with impaired glucose tolerance and/or hyperglycemia.
167-168. (canceled)
Dependencies are inferred from the claim text.